Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Rigel Pharmaceuticals Inc

NASDAQ: RIGL · Life Sciences · 1 alert · CIK 1034842

Share price
$43.73Close, Nov 16
Market cap
$823M
Shares outstanding
18.83MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Rigel Pharmaceuticals Inc filings on SEC EDGAR ↗

4:15 PM ET 8-K
Financial Results

Rigel Pharmaceuticals Financial Results

Rigel Pharmaceuticals reported Q3 2026 total revenues of $80.9 million, driven by $72.3 million in net product sales and the commercial launch of VEPPANU. The company achieved net income of $13.2 million for the quarter and updated its full-year 2026 revenue outlook to a range of $290 million to $295 million.

Term
Q3 2026

“VEPPANU’s launch marks an exciting and transformational milestone for Rigel and we are very pleased with the initial uptake. In the first six weeks of launch we shipped VEPPANU to more than 100 patients and clinics and have already seen many refills.”

Raul Rodriguez, Rigel’s president and CEO

“Our priorities are to build on the VEPPANU launch and advance R289 in lower-risk MDS, with updated Phase 1b data to be presented at ASH in December. We believe VEPPANU and R289 have significant commercial potential to further transform Rigel and drive long-term shareholder value.”

Raul Rodriguez, Rigel’s president and CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.